Peptide OH‐CATH30 Mitigates Cachexia‐Induced Muscle Atrophy via Modulation of TLR4‐Associated Inflammation
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Qiquan Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Control and Aging, Human Aging Research Institute and School of Life Science, Nanchang University and Jiangxi Key Laboratory of Aging and D…. Hauptthemen laut MEDLINE: Cachexia, Toll-Like Receptor 4, Muscular Atrophy, Inflammation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program, Ministry of Science and Technology of China, National Natural Science Foundation of China, Jiangxi Province.
Abstract (Originalsprache)
Background
Cachexia, characterized by severe weight loss and muscle atrophy, frequently occurs in chronic conditions such as sepsis, cancer and chemotherapy, with limited effective treatments. Despite similar clinical manifestations, the underlying mechanisms across different disease contexts remain unclear. Identifying common pathways could lead to novel therapies. This study examines the role of Toll‐like receptor 4 (TLR4), which is upregulated in various cachexia models, and assesses the therapeutic potential of the TLR4‐inhibiting peptide OH‐CATH30 in mitigating muscle atrophy.
Methods
In vivo models using 8‐week‐old mice treated with lipopolysaccharide (LPS), 4T1 tumour cells and cisplatin were used to investigate common pathways in cachexia. In vitro models were established by treating C2C12 myotubes with TNF‐α, 4T1 culture supernatants and cisplatin. OH‐CATH30's effects on muscle atrophy were assessed by measuring myotube diameter, grip strength, muscle weight and muscle fibre cross‐sectional area (CSA) via H&E staining. RNA‐seq, qPCR, ELISA and Western blotting were performed to explore pathways in cachexia‐induced muscle atrophy and OH‐CATH30's action mechanism.
Results
Transcriptomic analysis showed significant enrichment of inflammation and protein degradation pathways in skeletal muscle in LPS‐induced sepsis, 4T1 tumour‐induced cancer cachexia and cisplatin‐induced cachexia models, with upregulated expression of TLR4 pathway genes such as Cd14 , Tlr4 and Irak4 ( p < 0.05). In myotube atrophy models induced by TNF‐α, 4T1 and cisplatin, OH‐CATH30 significantly increased MyHC protein levels ( p < 0.05) and myotube diameter ( p < 0.05). In mouse cachexia models induced by LPS, 4T1 and cisplatin, OH‐CATH30 treatment significantly increased body weight ( p < 0.05), muscle weight ( p < 0.001), CSA ( p < 0.05) and improved grip strength ( p < 0.05). Transcriptomic analysis further revealed that OH‐CATH30 treatment downregulated expression of inflammation and protein degradation‐related genes across all cachexia models. In 4T1‐treated mice, qPCR confirmed OH‐CATH30 reduced mRNA levels of Il6 ( p = 0.05), Mstn ( p < 0.0001) and protein degradation genes such as Trim63 , Fbxo32 , Bnip3 , Gabarapl1 and Ulk1 ( p < 0.05). ELISA showed reduced serum IL‐6 levels, and Western blot confirmed downregulation of atrogin1 ( p < 0.05) and autophagy marker LC3II ( p < 0.05) with OH‐CATH30 treatment. Pharmacological inhibition of TLR4 using TAK‐242 recapitulated the protective effects of OH‐CATH30, with no additive benefit observed ( p > 0.05).
Conclusions
Our findings underscore the critical role of TLR4 signalling in cachexia‐associated muscle wasting across different disease contexts and demonstrate the efficacy of OH‐CATH30, a TLR4 inhibitor, in alleviating muscle atrophy in various cachexia models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Control and Aging, Human Aging Research Institute and School of Life Science, Nanchang University and Jiangxi Key Laboratory of Aging and Diseases, Nanchang, China.
- Department of Sports Medicine, The Beijing Jishuitan Hospital Guizhou Hospital, Guiyang, China.
- Department of Urology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- Department of Radiation Therapy, Yunnan Cancer Hospital/Third Affiliated Hospital of KunMing Medical University, Kunming, China.
- HeartSeek Biotechnology, Kunming, China.
- Institutional Center for Shared Technologies and Facilities of the Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, China.
ORCID-Profile: Yang Xiang
Förderung
- National Key R&D Program, Ministry of Science and Technology of China
- National Natural Science Foundation of China
- Jiangxi Province
- Guizhou Province (Qiankehebasis-ZK [2024] general 241)
- Key Medical Discipline Construction Project of Guizhou Provincial Health Commission
- Nanchang University
Zitieren
APA
Wang, Q., Li, J., Yang, M., Guo, C., Zhang, M., Huang, C., Wang, X., Zhang, D., Zeng, L., Ke, H., Wen, Y., Li, S., Lee, W., Zhao, L., Lan, X., & Xiang, Y. (2026). Peptide OH‐CATH30 Mitigates Cachexia‐Induced Muscle Atrophy via Modulation of TLR4‐Associated Inflammation. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70195
Vancouver
Wang Q, Li J, Yang M, Guo C, Zhang M, Huang C, et al. Peptide OH‐CATH30 Mitigates Cachexia‐Induced Muscle Atrophy via Modulation of TLR4‐Associated Inflammation. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70195
BibTeX
@article{Wang2026,
author = {Wang, Qiquan and Li, Jian and Yang, Mengqi and Guo, Caifen and Zhang, Ming and Huang, Chunping and Wang, Xiang and Zhang, Dongqin and Zeng, Lin and Ke, Hao and Wen, Yunling and Li, Shengan and Lee, Wenhui and Zhao, Limin and Lan, Xinqiang and Xiang, Yang},
title = {Peptide OH‐CATH30 Mitigates Cachexia‐Induced Muscle Atrophy via Modulation of TLR4‐Associated Inflammation},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70195}
}
EUVIMED